Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 1;10:1116862. doi: 10.3389/fmed.2023.1116862

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Colombo, Caviglia, Ravera, Tribocco, Frara, Rosso, Travelli, Genazzani and Ribaldone.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Serum eNAPRT levels and response to anti-TNF treatment in IBD patients. (A) eNAPRT levels in responders (R) and non-responders (NR) to adalimumab at baseline (T = 0) and after 3 months from the first infusion (T = 3). N = 62: CD = 58, UC = 4. (B) ROC curve of adalimumab response. (C) eNAPRT levels in single patients after adalimumab infusion. Red dots represent NR, green dots represent R. N = 62: CD = 58, UC = 4. (D) eNAPRT levels in R and NR to vedolizumab at baseline (T = 0) and after 3 months from the first infusion (T = 3). N = 40: CD = 23, UC = 17. (E) ROC curve of vedolizumab response. (F) eNAPRT levels in single patients after vedolizumab infusion. N = 40: CD = 23, UC = 17. Red dots represent NR, green dots represent R. P-value: *p < 0.05; ^**p < 0.01; ^***p < 0.001, and^****p < 0.0001.